JS207 + nab-paclitaxel

JS207 + nab-paclitaxel is a combination therapy under clinical investigation, most notably for triple-negative breast cancer. **JS207** is a novel drug candidate; available information suggests it is being tested in combination with **nab-paclitaxel**, a nanoparticle albumin-bound formulation of paclitaxel, a chemotherapy agent. Nab-paclitaxel works by stabilizing microtubules and inhibiting cell division, leading to apoptosis of cancer cells. The combination aims to leverage the anti-tumor activity of both agents, with nab-paclitaxel offering improved solubility and reduced toxicity compared to conventional paclitaxel. JS207’s exact mechanism has not been publicly detailed, but the combination is being evaluated in Phase II trials for efficacy and safety[6].

Other names

albumin-bound paclitaxel